Why did GSK terminate its neuroscience collaboration with Alector?

GSK terminated the collaboration after both experimental antibody drugs—latozinemab and nivisnebart—suffered clinical setbacks: latozinemab failed a late-stage study in a rare inherited form of frontotemporal dementia, and nivisnebart's mid-stage Alzheimer's disease trial was discontinued following an interim analysis showing it was unlikely to meet its primary goal.

What were the financial terms of the 2021 Alector–GSK collaboration agreement, and what is the timeline for termination?

Under the 2021 agreement, Alector received a $700 million upfront payment from GSK and was eligible for up to $1.5 billion in additional milestone payments and royalties; the termination, triggered by GSK's written notice on July 6, will take effect on January 2 next year after a 180-day notice period.

Alector and GSK End Partnership Following Dementia, Alzheimer's Drug Failures

Jul 8, 2026

GSK terminated its neuroscience collaboration with Alector after clinical failures of two antibody drugs for dementia and Alzheimer's. The move follows late-stage setbacks and led to significant workforce reductions at Alector.

reuters

2026-07-08

Alector and GSK End Partnership Following Dementia, Alzheimer's Drug Failures

Alector and GSK End Partnership Following Dementia, Alzheimer's Drug Failures

FAQ